On Monday, Cara Therapeutics Inc (NASDAQ: CARA) opened lower -3.76% from the last session, before settling in for the closing price of $0.32. Price fluctuations for CARA have ranged from $0.24 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 115.17%. Company’s average yearly earnings per share was noted 42.62% at the time writing. With a float of $45.73 million, this company’s outstanding shares have now reached $54.48 million.
Let’s determine the extent of company efficiency that accounts for 55 employees. In terms of profitability, gross margin is 72.84%, operating margin of -946.87%, and the pretax margin is -1010.19%.
Cara Therapeutics Inc (CARA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cara Therapeutics Inc is 16.62%, while institutional ownership is 32.60%. The most recent insider transaction that took place on Aug 01 ’24, was worth 1,452. In this transaction PRESIDENT AND CEO of this company sold 4,149 shares at a rate of $0.35, taking the stock ownership to the 172,436 shares. Before that another transaction happened on May 02 ’24, when Company’s PRESIDENT AND CEO sold 3,936 for $0.75, making the entire transaction worth $2,952. This insider now owns 176,585 shares in total.
Cara Therapeutics Inc (CARA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 42.62% per share during the next fiscal year.
Cara Therapeutics Inc (NASDAQ: CARA) Trading Performance Indicators
Check out the current performance indicators for Cara Therapeutics Inc (CARA). In the past quarter, the stock posted a quick ratio of 4.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.73 in one year’s time.
Technical Analysis of Cara Therapeutics Inc (CARA)
Looking closely at Cara Therapeutics Inc (NASDAQ: CARA), its last 5-days average volume was 0.28 million, which is a drop from its year-to-date volume of 0.68 million. As of the previous 9 days, the stock’s Stochastic %D was 12.16%. Additionally, its Average True Range was 0.02.
During the past 100 days, Cara Therapeutics Inc’s (CARA) raw stochastic average was set at 11.11%, which indicates a significant increase from 9.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.04% in the past 14 days, which was lower than the 129.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3359, while its 200-day Moving Average is $0.6385. However, in the short run, Cara Therapeutics Inc’s stock first resistance to watch stands at $0.3238. Second resistance stands at $0.3376. The third major resistance level sits at $0.3476. If the price goes on to break the first support level at $0.3000, it is likely to go to the next support level at $0.2900. Should the price break the second support level, the third support level stands at $0.2762.
Cara Therapeutics Inc (NASDAQ: CARA) Key Stats
There are currently 54,676K shares outstanding in the company with a market cap of 17.00 million. Presently, the company’s annual sales total 20,970 K according to its annual income of -118,510 K. Last quarter, the company’s sales amounted to 990 K and its income totaled -20,020 K.
